Valbiotis SA announced the signature of a research partnership in intestinal microbiota with the MEDIS(2) Unit from the Clermont Auvergne University on its active substances TOTUM--070 and TOTUM--448 against dyslipidemia and metabolic liver disease, partly financed by the French National Research Agency. Led by a laboratory shared by the two entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will provide exclusive data on the effects and modes of action of Valbiotis' plant-based substances at the intestinal level, in the context of non-drug strategies to combat metabolic and cardiovascular diseases.